Multicenter, randomized, phase III study comparing imatinib (Glivec) standard dose (400 mg/d) with imatinib high dose induction (800 mg/d) followed by imatinib maintenance (400 mg/d) in patients with pretreated Ph+/BCR-ABL(+) CML in chronic phase - Result

Rezultati

Naziv:	Multicenter, randomized, phase III study comparing imatinib (Glivec) standard dose (400 mg/d) with imatinib high dose induction (800 mg/d) followed by imatinib maintenance (400 mg/d) in patients with pretreated Ph+/BCR-ABL(+) CML in chronic phase - Result
Autori:	Petzer, Andreas L; Wolf, Dominik; Fong, Dominic; Lion, Thomas; Dyagil, Irina; Masliak, Zvenyslava; Boskovic, Darinka V; Griskevicius, Laimonas; Lejniece, Sandra; Spasov, Emil; Gercheva, Liana; Stojanovic, Aleksandar; Peytchev, Dontcho; Tzvetkov, Nikolay; Griniute, Rasa; Stanchev, Atanas; Kwakkelstein, Martin; Ulmer, Hanno; Gastl, Guenther A;
Godina:	2007
Publikacija:	BLOOD
ISSN:	0006-4971 Blood Pretraži identifikator
Tip rezultata:	Konferencijski rad
Kolacija:	vol. 110 br. 11 str. 1048-1048
DOI:	10.1182/blood.V110.11.1048.1048
WoS-ID:	000251100801317
URI:	https://enauka.gov.rs/handle/123456789/796875
Izvor metapodataka:	(Preuzeto iz Nasi u WoS)
M-kategorija:	Mp kategorija će biti prikazana naknadno.

Alt metrika

Dimensions

Unpaywall

Google Scholar^TM

Rezultati na eNauka su zaštićeni autorskim pravima i sva prava su zadržana, osim ako nije drugačije naznačeno.